We will be contrasting the differences between Avadel Pharmaceuticals plc (NASDAQ:AVDL) and Myovant Sciences Ltd. (NYSE:MYOV) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avadel Pharmaceuticals plc||86.41M||1.31||96.09M||-2.57||0.00|
|Myovant Sciences Ltd.||N/A||0.00||273.55M||-3.80||0.00|
Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Avadel Pharmaceuticals plc and Myovant Sciences Ltd.
Table 2 shows Avadel Pharmaceuticals plc and Myovant Sciences Ltd.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Avadel Pharmaceuticals plc||-111.20%||-67.8%||-14.3%|
|Myovant Sciences Ltd.||0.00%||-451.3%||-153.5%|
The current Quick Ratio of Avadel Pharmaceuticals plc is 3.1 while its Current Ratio is 3.3. Meanwhile, Myovant Sciences Ltd. has a Current Ratio of 3.5 while its Quick Ratio is 3.5. Myovant Sciences Ltd. is better positioned to pay off its short-term and long-term debts than Avadel Pharmaceuticals plc.
In next table is given Avadel Pharmaceuticals plc and Myovant Sciences Ltd.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Avadel Pharmaceuticals plc||0||0||0||0.00|
|Myovant Sciences Ltd.||0||0||1||3.00|
Myovant Sciences Ltd. on the other hand boasts of a $25 average price target and a 179.64% potential upside.
Institutional & Insider Ownership
Roughly 54.9% of Avadel Pharmaceuticals plc shares are owned by institutional investors while 31.6% of Myovant Sciences Ltd. are owned by institutional investors. Insiders owned 0.9% of Avadel Pharmaceuticals plc shares. Insiders Competitively, owned 0.1% of Myovant Sciences Ltd. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Avadel Pharmaceuticals plc||10%||9.09%||-34.98%||-63.23%||-81.2%||-48.84%|
|Myovant Sciences Ltd.||-25.52%||-35.45%||-36.99%||-29.12%||-38.31%||-17.67%|
For the past year Avadel Pharmaceuticals plc was more bearish than Myovant Sciences Ltd.
On 6 of the 10 factors Avadel Pharmaceuticals plc beats Myovant Sciences Ltd.
Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The companyÂ’s owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection. The company also provides Karbinal ER, an H1 receptor antagonist used to treat children with seasonal and perennial allergic rhinitis; AcipHex Sprinkle for the treatment of gastroesophageal reflux disease; Flexichamber, a collapsible holding chamber that administers aerosolized medication from pressurized metered dose inhalers; and Cefaclor for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections. In addition, its product candidates comprise sodium oxybate for narcolepsy; Hydromorphone/Trigger Lock for pain; Exenatide, a Medusa-based injectable formulation for diabetes; and LiquiTime for cough/cold. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.